Search

Author/Creator Simpson, Tyler

2. Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. (4th November 2015)

Authors:
Harvey, Christopher; Elpek, Kutlu; Duong, Ellen; Simpson, Tyler; Shu, ChengYi J; Shallberg, Lindsey; Wallace, Matthew; Sathyanarayanan, Sriram; Mabry, Robert; Briskin, Michael; Michaelson, Jennifer; Gajewski, Thomas F
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Issue 2 (December 2015)

Authors:
Harvey, Christopher; Elpek, Kutlu; Duong, Ellen; Simpson, Tyler; Shu, ChengYi; Shallberg, Lindsey; Wallace, Matthew; Sathyanarayanan, Sriram; Mabry, Robert; Briskin, Michael; Michaelson, Jennifer; Gajewski, Thomas
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗